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INTRODUCTION
Retroperitoneal soft tissue sarcomas are relatively uncommon, 
accounting for 10–15% of all soft tissue sarcomas and 30% of 
all malignant retroperitoneal tumors.1 Surgical resection is the 
standard curative treatment for patients with localized dis-
ease. However, retroperitoneal sarcoma is often diagnosed in 
the advanced stage, as it is frequently asymptomatic. More-
over, it makes complete excision difficult. Complete resection 
with negative margins is essential to increase survival, even if 
resection of adjacent organs cannot be avoided.2-4 The rate of 
complete resection ranges from 41.8% to 76%.4-6 Even after 
complete resection, local recurrence remains the most com-
mon cause of failure and is ultimately fatal, with a mortality rate 
of 20–75%.7 
To improve local control as well as survival, several neoad-
juvant or adjuvant treatments have been investigated. The ra-
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tionale for applying perioperative radiotherapy (RT) in addi-
tion to surgery comes from small randomized controlled trials 
and several retrospective studies that provide evidence for 
improved local control with RT in soft tissue sarcoma without 
affecting survival.8,9 Postoperative RT (PORT) is clinically used 
infrequently, since it has higher complication rate compared 
to preoperative RT.10 However, RT techniques used in previ-
ous studies were relatively old-fashioned, mostly composed 
of two-dimensional techniques using anterioposterior (AP)/
posterioanterior (PA) beams. Currently, three-dimensional-
conformal RT (3D-CRT) and intensity-modulated RT (IMRT) 
are used, which facilitate normal organ sparing. It is necessary 
to reexamine the role of PORT in the modern era, where more 
sophisticated techniques and conformal treatment planning 
are possible. In this study, we investigated the efficacy of PORT 
using modern techniques in patients with retroperitoneal soft 
tissue sarcoma.
MATERIALS AND METHODS
Patient characteristics
One hundred patients, who underwent surgical resection for 
primary retroperitoneal soft tissue sarcoma between 1994 and 
2015 at Yonsei Cancer Center, were retrospectively reviewed. 
We included only patients who were treated after 1994, as 3D-
CRT has been employed since 1994 at our institution. Twenty 
patients were excluded from this analysis due to initial stage IV 
(11 patients), no follow-up after surgery (six patients), or dou-
ble primary malignancy (three patients). Finally, a total of 80 
patients were included in our analysis, and their demographic 
characteristics, clinicopathological parameters, and treatment 
variables were obtained from electronic medical records. 
Pre and postoperative imaging studies included computed 
tomography (CT) and/or magnetic resonance imaging (MRI). 
Tumor staging was performed in accordance with the seventh 
edition of American Joint Committee on Cancer staging sys-
tem for soft tissue sarcoma. Histopathologic subtypes were 
subdivided into leiomyosarcoma, liposarcoma, undifferenti-
ated pleomorphic sarcoma, and others, due to the small num-
ber of other rare sarcoma subtypes. Histologic grading was 
performed according to Fédération Nationale des Centres de 
Lutte Contre le Cancer (FNCLCC) grading system. Tumor size 
was defined as the maximum dimension on cross-sectional 
imaging for a solitary mass, and as the sum of all maximum 
dimensions for more than one mass. This study was approved 
by Institutional Review Board of Yonsei University Health Sys-
tem (IRB-4-2017-1060). Patients’ records/information were 
anonymized and de-identified prior to analysis, and informed 
consent was not obtained from each participant.
Treatment
All patients underwent surgical resection as initial treatment. 
Surgical resection was intended to achieve a negative margin, 
even if resection of adjacent organs was needed. Surgical mar-
gins were categorized as R0 (histologically negative margin), 
R1 (macroscopically negative, but microscopically positive 
margin), and R2 (macroscopically positive margin). 
PORT was performed in 38 patients (47.5%) using 3D-CRT 
in 29 patients and IMRT in 9 patients, with a conventional 
fractionation schedule (1.8–2.6 Gy per fraction, once per day, 
5 days per week). IMRT was delivered with helical TomoTher-
apy (Tomotherapy, Inc., Madison, WI, USA) or Volumetric 
Arc-Therapy. Tumor bed was delineated using MRI or CT fu-
sion on either MIM software (MIM Software, Cleveland, OH, 
USA) or Pinnacle Radiotherapy Planning System (Phillips 
Medical System, Andover, MA, USA). CT simulation and re-
producible patient immobilization were essential. A four-di-
mensional CT (4D-CT) scan was acquired for the assessment 
of respiratory movement.
Clinical target volume (CTV) was determined by allowing a 
margin of at least 2 cm to tumor bed, considering the postop-
erative anatomic change individually. We did not take into ac-
count preoperative tumor volume. Internal target volume 
(ITV) was delineated, taking account of respiratory movement 
if 4D-CT was used. Planning target volume included CTV or 
ITV, plus a 3 to 5-mm margin. Cone-down was performed in 
3D-CRT planning, and final target volume at the time of cone-
down was defined as tumor bed plus a 0.5-cm margin. In IMRT 
planning, simultaneous integrated boost (SIB) technique was 
used instead of cone-down. Radiation dose for initial target 
volume was considered to be 45 Gy for microscopic tumor 
control, which could be lowered individually considering nor-
mal tissue tolerance dose. Using either cone-down for 3D-CRT 
or SIB technique for IMRT, the total dose of radiation was ap-
proximately 54 Gy. Intended prescribed radiation dose was 60 
Gy or more, in the case of R1 or R2 resection. The most fre-
quent dose-limiting organ was small bowel, especially duode-
num, which was restricted to ≤45 Gy. We were not concerned 
about the dose to kidney near tumor bed, if patients had an-
other healthy kidney or if kidney was removed during surgical 
resection. RT plan was designed to be as conformal as possi-
ble, using multiple beam ports in 3D-CRT and intensity mod-
ulation in IMRT. Examples of RT plans at our institution are 
shown in Fig. 1.
Adjuvant chemotherapy was administered to 23 patients 
(28.8%), depending on the clinician’s discretion. All patients 
who were treated after year 2000 were administered doxoru-
bicin/ifosfamide, while three patients who were treated before 
2000 received other regimens. The use of adjuvant chemother-
apy was slightly higher in no-PORT group than in PORT group, 
without statistical significance (21.1%, PORT and 35.7%, no-
PORT; p=0.230). 
Follow-up
All patients were examined weekly during RT to monitor treat-
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ment-related toxicity and general condition. Imaging studies 
were conducted at 1 and 3 months after completion of the 
planned treatment. If there was no evidence of recurrence for 
1 year, patients were followed at 6-month intervals for the next 
2 years and annually thereafter. Treatment-related toxicities 
were recorded according to Common Toxicity Criteria for Ad-
verse Events (version 4.0). Recurrences were defined as either 
histologic confirmation of disease recurrence or, if pathologi-
cal confirmation was not performed, conclusive imaging dem-
onstrating recurrence. Local failure, defined as recurrence in 
retroperitoneal space, was divided into infield and outfield re-
currence, depending on the location of tumor in relation to RT 
target volume. Distant metastasis was defined as tumor recur-
rence outside of retroperitoneal space (i.e., chest, abdomen, 
peritoneum, brain, and elsewhere). 
A
B
C
Fig. 1. Examples of radiotherapy (RT) plan of (A) two-dimensional RT, (B) three-dimensional conformal RT, and (C) intensity-modulated RT.
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Statistical analysis
The primary endpoint was local failure-free survival (LFFS), 
and secondary endpoints were overall survival (OS) and RT-
related toxicities. Survival duration was calculated from the date 
of diagnosis to corresponding event (local failure or death). Lo-
cal failure was classified based on the location of recurrent tu-
mor: infield in event of tumor recurrence within RT target vol-
ume, marginal in event of recurrence inside initial target volume, 
but outside of cone-down volume, and outfield in event of recur-
rence outside RT target volume. We performed Pearson’s chi-
square test or Fisher’s exact test, as appropriate, for categorical 
variables, and independent t-tests for continuous variables to 
evaluate differences between the two groups (PORT and no-
PORT). Kaplan-Meier method with log-rank test and Cox regres-
sion were used to analyze survival outcomes between groups. 
Stepwise Cox proportional hazards regression was used to per-
form multivariable analysis on prognostic factors for LFFS and 
OS (inclusion criteria p<0.05, exclusion criteria p>0.1). All sta-
tistical tests were two-sided with significance defined as p<0.05. 
Data were analyzed using IBM SPSS software version 20.0 (IBM 
Corp., Armonk, NY, USA).
RESULTS
Patient and treatment characteristics
Patient and tumor characteristics are shown in Table 1. Pa-
tients’ ages ranged from 20 to 81 years, with a median age of 
55 years. The most common histologic subtype was liposarco-
ma (52.5%), followed by leiomyosarcoma (22.5%), undifferen-
tiated pleomorphic sarcoma (11.2%), and others (13.8%). Me-
dian tumor size was 13 cm (range, 2.7–40 cm). FNCLCC grade 
was reported in 52 patients (65%), with grade 1 in 17 patients 
(21.3%), grade 2 in 18 patients (22.4%), and grade 3 in 17 pa-
tients (21.3%). Surgical resection margin was R0 in 45 patients 
(56.2%), R1 in 24 patients (30%), and R2 in 11 patients (13.8%). 
After comparing the two groups (PORT vs. no-PORT), we found 
no significant differences in patient characteristics, although 
resection margin showed a marginal difference: rate of R1 or R2 
resection was higher in PORT group (p=0.053). There were more 
patients with FNCLCC grade 2 or 3 included in PORT group than 
in no-PORT group, but this was not significant (50% vs. 38%, p= 
0.432).
PORT was delivered with a median dose of 54 Gy (range, 
36.0–66.9 Gy) at a median 1.8 Gy per fraction (range, 1.8–2.6 
Gy). Radiation dose tended to be higher in patients with R1 or 
R2 resection than in those with R0 resection (Table 2). In PORT 
group, 57.1% of patients with R2 resection received >59.4 Gy of 
radiation, while half of the patients with R0 or R1 resection re-
ceived <50.4 Gy of radiation. Median doses of the two RT tech-
niques were the same (54 Gy), with a range of 36.0–66.0 Gy for 
3D-CRT and 45.0–66.9 Gy for IMRT.
Local control and survival outcomes
Median follow-up was 37.1 months (range, 2.5–207.9 months) 
for the entire cohort. The 2-year and 5-year LFFS rates were 
Table 1. Patient Characteristics 
No-PORT 
(n=42)
PORT 
(n=38)
Total 
(n=80)
p value
Age (yr) 53.7±15.3 52.7±15.4 53.2±15.3 0.782
Sex 0.111
Male 24 (57.1) 14 (36.8) 38 (47.5)
Female 18 (42.9) 24 (63.2) 42 (52.5)
ECOG 0.624
0 18 (42.9) 16 (42.1) 34 (42.5)
1 24 (57.1) 22 (57.9) 45 (56.2)
Pathology 0.096
Liposarcoma 27 (64.3) 15 (39.5) 42 (52.5)
Leiomyosarcoma 6 (14.3) 12 (31.6) 18 (22.5)
UPS 3 (7.1) 6 (15.8) 9 (11.2)
Other 6 (14.3) 5 (13.2) 11 (13.8)
FNCLCC grade     0.432
1 11 (26.3) 6 (15.8) 17 (21.3)
2 8 (19.0) 10 (26.3) 18 (22.4)
3 8 (19.0) 9 (23.7) 17 (21.3)
Unknown 15 (35.7) 13 (34.2) 28 (35.0)
Size 0.599
<10 cm 10 (23.8) 12 (31.6) 22 (27.5)
≥10 cm 32 (76.2) 26 (68.4) 58 (72.5)
Stage 0.358
IA 2 (4.8) 3 (7.9) 5 (6.2)
IB 22 (52.4) 12 (31.6) 34 (42.5)
IIA  0 (0.0) 1 (2.6) 1 (1.2)
IIB 7 (16.7) 9 (23.7) 16 (20.0)
III 11 (26.2) 13 (34.2) 24 (30.0)
Resection margin           0.053
R0 29 (69.0) 16 (42.1) 45 (56.2)
R1 9 (21.4) 15 (39.5) 24 (30.0)
R2 4 (9.5) 7 (18.4) 11 (13.8)
Adjuvant chemotherapy 0.230
No 27 (64.3) 30 (78.9) 57 (71.2)
Yes 15 (35.7) 8 (21.1) 23 (28.8)
PORT, postoperative radiotherapy; ECOG, Eastern Cooperative Oncology Group; 
UPS, undifferentiated pleomorphic sarcoma; FNCLCC, Fédération Nationale 
des Centres de Lutte Contre le Cancer.
Data are presented as mean±SD or number (%).
Table 2. Postoperative Radiation Dose according to Resection Margin 
Status
≤45 Gy 45–50.4 Gy 50.4–54 Gy 54–59.4 Gy >59.4 Gy Total
R0 6 (37.5) 2 (12.5) 5 (31.2) 1 (6.3) 2 (12.5) 16 
R1 3 (20.0) 4 (26.6) 1 (6.7) 6 (40.0) 1 (6.7) 15
R2 1 (14.3) 0 (0.0) 2 (28.6) 0 (0.0) 4 (57.1) 7
Total 10 6 8 7 7 38
Data are presented as number (%).
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63.9% and 47.9%, respectively. The 2-year and 5-year OS rates 
were 87.5% and 71.1%, respectively. In univariate analysis, tu-
mor stage [hazard ratio (HR) 1.53, 95% confidence interval (CI) 
1.07–2.19; p=0.021], FNCLCC grade (HR 2.31, 95% CI 1.28–
4.16; p=0.005), and use of PORT (HR 0.272, 95% CI 0.13–0.57; 
p=0.001) were significantly associated with LFFS. Among 
these, PORT was the only powerful prognostic factor associat-
ed with LFFS after adjusting for confounding factors in multi-
variate analysis (HR 0.179, 95% CI 0.07–0.49; p=0.001). LFFS 
was significantly better in PORT group; the 5-year LFFS rates 
were 74.2% for PORT group and 24.3% for no-PORT group (Fig. 
2A). However, there was no significant correlation between 
RT dose and LFFS. In univariate analysis for OS, tumor stage 
(HR 2.22, 95% CI 1.37–3.58; p=0.001) and FNCLCC grade (HR 
6.48, 95% CI 2.05–20.52; p=0.001) were significantly associated 
with OS, but the use of PORT was not prognostic for OS. The 
5-year OS rate was 71.6% for PORT group and 70.6% for no-
PORT group (p=0.604) (Fig. 2B). There was no significant prog-
nostic factor for OS in multivariate analysis. In particular, the 
use of chemotherapy was not beneficial in our analysis.
Patterns of failure 
Treatment failure occurred in 47 (58.8%) of 80 patients. The 
most common pattern of failure was local recurrence. Local 
recurrence occurred in 33 patients (41.3%), distant metastasis 
in eight patients (10%), and both in six patients (7.5%). Lung 
was the predominant site of distant metastasis, which was ob-
served in six patients, followed by peritoneal seeding in three 
patients and liver metastasis in two patients. The patterns of 
failure by resection margin are summarized in Fig. 3. Patients 
who did not receive PORT, despite R1 or R2 resection, experi-
enced more recurrences compared to those treated with 
PORT: 78% versus 47% in patients with R1 resection and 100% 
versus 67% in those with R2 resection for no-PORT and PORT 
groups, respectively. In regard to local recurrence, the differ-
ence became more apparent across all resection margin sta-
tuses. Local recurrence occurred in 55% of no-PORT group and 
32% of PORT group in R0 patients, and 78% of no-PORT group 
and 27% of PORT group in R1 patients. All R2 patients who did 
not receive PORT had local recurrence, while 43% of PORT 
group had local recurrence. 
Of the 12 patients who experienced local recurrence after 
PORT, eight had infield recurrence, two had marginal recur-
rence, and two had outfield recurrence. There was no signifi-
cant correlation between resection margin status and the pat-
tern of local recurrence; infield recurrence occurred in three 
patients, each whom achieved R0 and R1 resection and two 
patients who achieved R2 resection; marginal recurrence oc-
curred in one patient, each of whom achieved R0 and R2 re-
section; and outfield recurrence occurred in one patient, each 
of whom achieved R0 and R1 resection. We also analyzed 
whether radiation dose was related to recurrence pattern. Me-
dian radiation dose was 45 Gy (range, 45–57 Gy) in patients 
with infield recurrence, while it was 50.4 Gy and 65 Gy for the 
two patients with marginal recurrence and 54 Gy and 59.4 Gy 
for the two patients with outfield recurrence. 
Acute and late toxicities
Radiation-related acute toxicities were observed in 24 of 38 pa-
tients who received PORT (63%). Grade ≤2 enteritis and anorex-
ia were observed in 13 patients and seven patients, respective-
ly. Four patients experienced grade ≤2 nausea/vomiting, but 
there was no acute toxicity ≥grade 3 observed. In regard to late 
complications, there were only two patients who had late com-
100
80
60
40
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0
100
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  PORT
  No-PORT
  PORT
  No-PORT
0                12                24                36                48                60                72
Months MonthsA B
Fig. 2. Kaplan-Meire curves for (A) LFFS and (B) OS.  LFFS, local failure-free survival; OS, overall survival.
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plication. One patient who received 65 Gy in 25 fractions to re-
sidual tumor mass at right psoas muscle experienced neurop-
athy extending to right leg, although residual tumor was well-
controlled until the last follow-up (over 9 years). In another 
patient who had neuropathy with right leg tingling sensation, it 
was difficult to distinguish radiation toxicity from surgical mor-
bidity since it occurred after surgical resection and persisted.
DISCUSSION
We found that PORT significantly improved LFFS in patients 
who received surgical resection for retroperitoneal soft tissue 
sarcoma. The benefit was more prominent in patients with R1 
and R2 resection, but PORT significantly improved local tumor 
control even in patients with R0 resection. Moreover, there 
were no RT-related toxicities ≥grade 3. Using modern RT tech-
niques, including 3D-CRT and IMRT, we could perform PORT 
safely without increasing complications. 
The effects of PORT on local control have been demonstrat-
ed in three prospective studies conducted in extremity sarco-
mas, which are the most common type of soft tissue sarcoma.8,9,11 
However, there has been no prospective study investigating the 
effect of PORT in retroperitoneal soft tissue sarcomas, so it is 
still subject to debate. Through several retrospective studies, 
the role of preoperative and postoperative RT has been inves-
tigated.5,7,12-15 Sampath, et al.13 reported the results from a multi-
institutional study of 251 patients, which revealed a significant 
improvement in LFFS in PORT arm over surgery alone; the 5- 
year LFFS was 64% in no-RT group and 79% in RT group. An-
other retrospective study from Scandinavian Sarcoma Group 
demonstrated a statistically significant difference in 5-year LRFS 
between RT group (77%) and no-RT group (39%) (p< 0.001).16
Our finding that RT acts as a significant prognostic factor for 
local control concurs with the findings of these previous stud-
ies. In our study, the 5-year LFFS was 74% in PORT group and 
24% in no-PORT group (p=0.001), and PORT was the stron-
gest prognostic factor for LFFS in multivariate analysis, over-
taking both FNCLCC grade and tumor stage. On the contrary, 
Choi, et al.17 showed that PORT had no benefit on disease-
specific survival, based on analysis of a relatively large number 
of patients using propensity-scoring matching from Surveil-
lance, Epidemiology, and End Results (SEER) database. How-
ever, this study included patients who had been treated with 
older techniques and lacked details about surgical margin, 
pathological risk factors, and RT technique. 
Although PORT significantly improved LFFS, the benefit 
did not lead to improved OS in our study. In case of local re-
currence, which was the most common cause of failure, sal-
vage treatment was actively performed, this may have diluted 
the difference in OS. Of the 33 patients who had only local re-
currence, 24 had not undergone PORT. Of these, 10 patients 
underwent surgery followed by PORT as salvage treatment 
and only two died after 5 and 42 months, with the 5-year OS 
rate of 67.5%. Moreover, five patients received salvage RT with-
out surgery, of whom only one died after 13 months and others 
were alive until last follow-up at 12, 62, 71, and 108 months. 
This suggests that salvage surgery followed by PORT could be 
an effective treatment even if relapsed.
The optimal timing of RT remains a controversy. The ratio-
Retroperitoneal soft tissue sarcoma 
treated with surgical resection (n=80)
No RT 
(n=29, 64%)
No RT 
(n=9, 39%)
No RT 
(n=4, 36%)
RT 
(n=16, 36%)
RT 
(n=15, 61%)
RT 
(n=7, 64%)
Recurrence 
(-)                     (+)
13 (45%)          16 (55%)               7 (43%)            9 (57%)             2 (22%)           7 (78%)           8 (53%)           7 (47%)           0 (0%)          4 (100%)         3 (43%)           4 (67%)
15     1                                        4       1        4                             6        1                                   3        1       3                         3       1                                   2       1       1
LF            DM                             LF             DM                            LF            DM                         LF             DM                       LF            DM                        LF            DM 
Recurrence 
(-)                     (+)
Recurrence 
(-)                     (+)
Recurrence 
(-)                     (+)
Recurrence 
(-)                     (+)
Recurrence 
(-)                     (+)
R0 (n=45) R1 (n=24) R2 (n=11)
Fig. 3. Pattern of failures according to resection margin and use of postoperative RT. RT, radiotherapy; LF, local failure; DM, distant metastasis.
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nale for preoperative radiation is that treatment volume is less 
extensive than with PORT, as only clinically and radiographi-
cally demonstrated tumor is included in target volume, and 
tumor often displaces bowel out of radiation field, so as to al-
low a lower dose to the normal tissue.18,19 Moreover, resection 
could also be less extensive than if surgery was performed af-
ter RT. However, we have to consider that radiation beam ar-
rangement prior to the development of 3D-CRT consisted of 
AP/PA beam, such that PORT contained a relatively large 
amount of bowel in RT field compared to preoperative RT. Cur-
rent technologies overcome this disadvantage and give a high-
er dose to target volume. One advantage of PORT is that the 
pathologist has an intact tumor specimen for determination 
of histologic grade and type, which will allow the clinical team 
to better determine the proper postoperative treatment. Addi-
tionally, there is no delay of surgery, which can be an emotion-
al advantage for some patients. Several studies have investigat-
ed whether preoperative or postoperative RT provides better 
outcomes.20-24 Zlotecki, et al.24 suggested that preoperative RT 
may be preferred, with similar clinical outcomes and less risk 
of complications than PORT. However, this study has several 
limitations; most patients were treated before 1990, when CT-
based treatment planning became standard, and patients who 
received preoperative RT were primarily seen after 1994. On 
the contrary, the largest study of a nationwide clinical oncolo-
gy database revealed that perioperative RT, whether preopera-
tive or postoperative, was associated with improved OS com-
pared with surgery alone.25 It is hard to conclude whether 
preoperative and postoperative RT is preferable based on pre-
vious studies, as they are all retrospective studies including a 
relatively small number of patients and show conflicting re-
sults. The ongoing randomized European Organization for Re-
search and Treatment of Cancer trial investigating 50.4 Gy of 
preoperative RT and surgery versus surgery alone for retroper-
itoneal sarcoma may provide additional insight into this issue 
(EORTC 62092-22092; STRASS trial; NCT01344018).
In practice, many clinicians dislike the use of PORT due to 
its higher complication rate compared with preoperative RT. 
Overall, the rate of acute PORT-induced enteritis is reported 
to be 30–80%, and grade 3 or 4 enteritis is present in approxi-
mately 6–80% of patients.24,26 However, most studies do not re-
flect the latest advances in RT technique, since they include a 
large number of patients treated before 3D-CRT was commonly 
used. In our study, acute toxicities were reported in 63% of pa-
tients, but no grade ≥3 toxicities were observed. Late toxicity 
was observed in only one patient who received high dose (>65 
Gy) of radiation. A study from M.D. Anderson Cancer Center, 
which investigated 121 patients treated between 1965 and 2012, 
reported a 10-year actuarial complication rate of 5%, and all 
complications occurred in patients treated between 1965 and 
1985.10
Although most studies have shown that RT is helpful for lo-
cal tumor control, there is a lack of consensus on the optimal 
radiation dose and target volume. Most institutions treat pa-
tients individually according to their institutional protocols. 
The postoperative radiation dose reported in previous studies 
is approximately 45–55 Gy.15,16,26 According to the treatment 
guideline for preoperative RT for retroperitoneal sarcoma pub-
lished in 2015,27 50 Gy is recommended as a reasonable dose 
based on panel discussion, due to lack of data. However, there 
is no consensus guideline on an optimal radiation dose for 
PORT. Some small retrospective studies have investigated an 
optimal radiation dose. Fein, et al.28 recommended a radiation 
dose ≥55.2 Gy, based on the higher local recurrence rate in 
patients receiving radiation <55.2 Gy. On the other hand, Ballo, 
et al.29 reported that a higher dose of radiation (>60 Gy) in-
creased toxicities, but not local control. In our study, it was dif-
ficult to draw a solid conclusion about the optimal radiation 
dose, due to the small number of patients included. Our results 
suggest that a radiation dose >45 Gy is necessary to achieve 
local control, considering that most of the infield recurrences 
occurred in patients who received ≤45 Gy to tumor bed, even 
in R0 patients, while patients who received radiation >45 Gy 
had marginal or outfield recurrences only. Among nine pa-
tients who received PORT for R2 resection, five received ≤54 Gy 
and four received ≥65 Gy. Four of the five patients who received 
≤54 Gy had local recurrence (infield in three patients, margin-
al recurrence in one patient), while only one marginal recur-
rence occurred among those who received ≥65 Gy. For those 
who received ≥65 Gy, no grade ≥3 toxicities were observed, 
and only one patient experienced neuropathy as late compli-
cation, without any tumor recurrence. This may suggest that a 
radiation dose ≥65 Gy is necessary for patients with R2 resec-
tion. To clarify the optimal dose, further well-designed large 
studies are needed. 
This study has several limitations driven from its retrospec-
tive nature. First, there are inherent selection biases, as with any 
retrospective study. Second, the number of patients included in 
this study was relatively small due to the low incidence of ret-
roperitoneal soft tissue sarcoma, and the treatment spanned 
several decades, which can affect the outcomes. However, our 
study’s strength is the exclusive inclusion of patients with pri-
mary retroperitoneal sarcoma treated with surgical resection 
and RT using a modern technique as primary treatment in a 
single institution. 
In conclusion, PORT markedly reduced local recurrence in 
retroperitoneal sarcoma patients. We suggest that PORT can 
be a safe treatment option in surgically resected retroperito-
neal sarcoma patients without increasing toxicity, if a confor-
mal and safe treatment plan is performed using modern RT 
techniques. The optimal RT technique in terms of timing, dose, 
and target volume should be further investigated.
ORCID
Chang-Ok Suh https://orcid.org/0000-0002-3375-7072
1056
PORT in Retroperitoneal Soft Tissue Sarcoma
https://doi.org/10.3349/ymj.2018.59.9.1049
REFERENCES
1. Clark JA, Tepper JE. Role of radiation therapy in retroperitoneal 
sarcomas. Oncology (Williston Park) 1996;10:1867-72.
2. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype 
and margin of resection predict pattern of recurrence and survival 
for retroperitoneal liposarcoma. Ann Surg 2003;238:358-70.
3. Storm FK, Mahvi DM. Diagnosis and management of retroperito-
neal soft-tissue sarcoma. Ann Surg 1991;214:2-10.
4. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal 
soft-tissue sarcoma: analysis of 500 patients treated and followed 
at a single institution. Ann Surg 1998;228:355-65.
5. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon 
F, et al. Prognostic factors in retroperitoneal sarcoma: a multivari-
ate analysis of a series of 165 patients of the French Cancer Center 
Federation Sarcoma Group. Cancer 2001;92:359-68.
6. Toulmonde M, Bonvalot S, Méeus P, Stoeckle E, Riou O, Isambert 
N, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, 
prognostic factors and focus on main histological subtypes: a mul-
ticenter analysis of the French Sarcoma Group. Ann Oncol 2014;25: 
735-42.
7. Van De Voorde L, Delrue L, van Eijkeren M, De Meerleer G. Radio-
therapy and surgery-an indispensable duo in the treatment of ret-
roperitoneal sarcoma. Cancer 2011;117:4355-64. 
8. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, 
Brennan MF. Long-term results of a prospective randomized trial 
of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 
1996;14:859-68.
9. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian 
SL, et al. Randomized prospective study of the benefit of adjuvant 
radiation therapy in the treatment of soft tissue sarcomas of the 
extremity. J Clin Oncol 1998;16:197-203.
10. Bishop AJ, Zagars GK, Torres KE, Hunt KK, Cormier JN, Feig BW, 
et al. Combined modality management of retroperitoneal sarco-
mas: a single-institution series of 121 patients. Int J Radiat Oncol 
Biol Phys 2015;93:158-65.
11. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, 
et al. The treatment of soft-tissue sarcomas of the extremities: pro-
spective randomized evaluations of (1) limb-sparing surgery plus 
radiation therapy compared with amputation and (2) the role of 
adjuvant chemotherapy. Ann Surg 1982;196:305-15.
12. Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper 
ES, et al. Prognostic factors associated with long-term survival for 
retroperitoneal sarcoma: implications for management. J Clin 
Oncol 1997;15:2832-9.
13. Sampath S, Hitchcock YJ, Shrieve DC, Randall RL, Schultheiss TE, 
Wong JY. Radiotherapy and extent of surgical resection in retro-
peritoneal soft-tissue sarcoma: multi-institutional analysis of 261 
patients. J Surg Oncol 2010;101:345-50. 
14. Pierie JP, Betensky RA, Choudry U, Willett CG, Souba WW, Ott MJ. 
Outcomes in a series of 103 retroperitoneal sarcomas. Eur J Surg 
Oncol 2006;32:1235-41. 
15. Le Péchoux C, Musat E, Baey C, Al Mokhles H, Terrier P, Domont J, 
et al. Should adjuvant radiotherapy be administered in addition to 
front-line aggressive surgery (FAS) in patients with primary retro-
peritoneal sarcoma? Ann Oncol 2013;24:832-7. 
16. Trovik LH, Ovrebo K, Almquist M, Haugland HK, Rissler P, Eide J, 
et al. Adjuvant radiotherapy in retroperitoneal sarcomas. A Scandi-
navian Sarcoma Group study of 97 patients. Acta Oncol 2014;53: 
1165-72. 
17. Choi AH, Barnholtz-Sloan JS, Kim JA. Effect of radiation therapy 
on survival in surgically resected retroperitoneal sarcoma: a pro-
pensity score-adjusted SEER analysis. Ann Oncol 2012;23:2449-57. 
18. Pawlik TM, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, 
et al. Long-term results of two prospective trials of preoperative 
external beam radiotherapy for localized intermediate- or high-
grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 2006;13: 
508-17.
19. Tzeng CW, Fiveash JB, Popple RA, Arnoletti JP, Russo SM, Urist 
MM, et al. Preoperative radiation therapy with selective dose es-
calation to the margin at risk for retroperitoneal sarcoma. Cancer 
2006;107:371-9.
20. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin 
RS. Preoperative vs. postoperative radiation therapy for soft tissue 
sarcoma: a retrospective comparative evaluation of disease out-
come. Int J Radiat Oncol Biol Phys 2003;56:482-8.
21. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue 
sarcomas: preoperative versus postoperative radiotherapy. J Surg 
Oncol 1996;61:90-9.
22. Sampath S, Schultheiss TE, Hitchcock YJ, Randall RL, Shrieve DC, 
Wong JY. Preoperative versus postoperative radiotherapy in soft-
tissue sarcoma: multi-institutional analysis of 821 patients. Int J 
Radiat Oncol Biol Phys 2011;81:498-505.
23. Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters 
PW. Preoperative vs. postoperative radiotherapy in the treatment 
of soft tissue sarcomas: a matter of presentation. Int J Radiat On-
col Biol Phys 1998;42:563-72.
24. Zlotecki RA, Katz TS, Morris CG, Lind DS, Hochwald SN. Adjuvant 
radiation therapy for resectable retroperitoneal soft tissue sarco-
ma: the University of Florida experience. Am J Clin Oncol 2005;28: 
310-6.
25. Nussbaum DP, Rushing CN, Lane WO, Cardona DM, Kirsch DG, 
Peterson BL, et al. Preoperative or postoperative radiotherapy 
versus surgery alone for retroperitoneal sarcoma: a case-control, 
propensity score-matched analysis of a nationwide clinical oncol-
ogy database. Lancet Oncol 2016;17:966-75. 
26. Gilbeau L, Kantor G, Stoeckle E, Lagarde P, Thomas L, Kind M, et 
al. Surgical resection and radiotherapy for primary retroperitone-
al soft tissue sarcoma. Radiother Oncol 2002;65:137-43.
27. Baldini EH, Wang D, Haas RL, Catton CN, Indelicato DJ, Kirsch 
DG, et al. Treatment guidelines for preoperative radiation therapy 
for retroperitoneal sarcoma: preliminary consensus of an interna-
tional expert panel. Int J Radiat Oncol Biol Phys 2015;92:602-12.
28. Fein DA, Corn BW, Lanciano RM, Herbert SH, Hoffman JP, Coia 
LR. Management of retroperitoneal sarcomas: does dose escala-
tion impact on locoregional control? Int J Radiat Oncol Biol Phys 
1995;31:129-34.
29. Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier 
JN, et al. Retroperitoneal soft tissue sarcoma: an analysis of radia-
tion and surgical treatment. Int J Radiat Oncol Biol Phys 2007;67: 
158-63.
